These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20527658)

  • 1. High dose atorvastatin after stroke or transient ischaemic attack (SPARCL)--does every stroke patient in Pakistan deserve a statin?
    Khan M; Kamran KA
    J Pak Med Assoc; 2010 Jun; 60(6):505-6. PubMed ID: 20527658
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
    Amarenco P; Callahan A; Campese VM; Goldstein LB; Hennerici MG; Messig M; Sillesen H; Welch KM; Wilson DJ; Zivin JA
    Stroke; 2014 Oct; 45(10):2974-82. PubMed ID: 25147328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stroke--an equal opportunity for the initiation of statin therapy.
    Kent DM
    N Engl J Med; 2006 Aug; 355(6):613-5. PubMed ID: 16899782
    [No Abstract]   [Full Text] [Related]  

  • 4. Atorvastatin in stroke: a review of SPARCL and subgroup analysis.
    Huisa BN; Stemer AB; Zivin JA
    Vasc Health Risk Manag; 2010 Apr; 6():229-36. PubMed ID: 20407630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atorvastatin for stroke prevention.
    Med Lett Drugs Ther; 2006 Sep; 48(1243):75-6. PubMed ID: 16977287
    [No Abstract]   [Full Text] [Related]  

  • 6. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; O'Neill BJ; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
    Atherosclerosis; 2009 Jun; 204(2):515-20. PubMed ID: 18962621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Sillesen H; Amarenco P; Hennerici MG; Callahan A; Goldstein LB; Zivin J; Messig M; Welch KM;
    Stroke; 2008 Dec; 39(12):3297-302. PubMed ID: 18845807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.
    ; Karam JG; Loney-Hutchinson L; McFarlane SI
    J Cardiometab Syndr; 2008; 3(1):68-9. PubMed ID: 18326981
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Callahan A; Amarenco P; Goldstein LB; Sillesen H; Messig M; Samsa GP; Altafullah I; Ledbetter LY; MacLeod MJ; Scott R; Hennerici M; Zivin JA; Welch KM;
    Arch Neurol; 2011 Oct; 68(10):1245-51. PubMed ID: 21670382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
    Chaturvedi S; Zivin J; Breazna A; Amarenco P; Callahan A; Goldstein LB; Hennerici M; Sillesen H; Rudolph A; Welch MA;
    Neurology; 2009 Feb; 72(8):688-94. PubMed ID: 18768917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin therapy after stroke or transient ischemic attack.
    Elkind MS
    N Engl J Med; 2006 Nov; 355(22):2369; author reply 2370-1. PubMed ID: 17139774
    [No Abstract]   [Full Text] [Related]  

  • 12. Statin therapy after stroke or transient ischemic attack.
    Mascitelli L; Pezzetta F
    N Engl J Med; 2006 Nov; 355(22):2369-70; author reply 2370-1. PubMed ID: 17139772
    [No Abstract]   [Full Text] [Related]  

  • 13. Atorvastatin in prevention of stroke and transient ischaemic attack.
    Amarenco P
    Expert Opin Pharmacother; 2007 Nov; 8(16):2789-97. PubMed ID: 17956199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atorvastatin treatment and carotid plaque morphology in first-ever atherosclerotic transient ischemic attack/stroke: a case-control study.
    Marchione P; Vento C; Morreale M; Izzo C; Maugeri A; Manuppella F; Romeo T; Giacomini P
    J Stroke Cerebrovasc Dis; 2015 Jan; 24(1):138-43. PubMed ID: 25440329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [After TIA and stroke: a statin for secondary prevention?].
    MMW Fortschr Med; 2006 Jun; 148(24):10. PubMed ID: 16850798
    [No Abstract]   [Full Text] [Related]  

  • 16. Statin therapy after stroke or transient ischemic attack.
    Khan NA
    N Engl J Med; 2006 Nov; 355(22):2369; author reply 2370-1. PubMed ID: 17139773
    [No Abstract]   [Full Text] [Related]  

  • 17. Statins after transient ischaemic attack and ischaemic stroke.
    Hankey GJ
    Lancet Neurol; 2006 Oct; 5(10):810-2. PubMed ID: 16987726
    [No Abstract]   [Full Text] [Related]  

  • 18. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study.
    Amarenco P; Bogousslavsky J; Callahan AS; Goldstein L; Hennerici M; Sillsen H; Welch MA; Zivin J;
    Cerebrovasc Dis; 2003; 16(4):389-95. PubMed ID: 14584489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of the SPARCL trial and its subanalyses.
    Welch KM
    Curr Atheroscler Rep; 2009 Jul; 11(4):315-21. PubMed ID: 19500496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial.
    Kongnakorn T; Ward A; Roberts CS; O'Brien JA; Proskorovsky I; Caro JJ
    Value Health; 2009 Sep; 12(6):880-7. PubMed ID: 19490555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.